Clinical Trial: Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL

Official Title: A Pilot Study of Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

Brief Summary: The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).

Detailed Summary:
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Current Primary Outcome: Overall response rate is defined as the rate of achieving best response of CR or PR, and will be summarized for participants who have received any dose of study drug

Original Primary Outcome: Overall response rate is defined as the rate of achieving best response of CR or PR, and will be summarized for participants who have received any dose of study drug

Current Secondary Outcome:

Original Secondary Outcome:

Information By: H. Lee Moffitt Cancer Center and Research Institute

Dates:
Date Received: March 30, 2022
Date Started: February 15, 2023
Date Completion: February 15, 2023
Last Updated: December 04, 2023
Last Verified: December 01, 2023